MX2023000763A - Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas. - Google Patents

Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.

Info

Publication number
MX2023000763A
MX2023000763A MX2023000763A MX2023000763A MX2023000763A MX 2023000763 A MX2023000763 A MX 2023000763A MX 2023000763 A MX2023000763 A MX 2023000763A MX 2023000763 A MX2023000763 A MX 2023000763A MX 2023000763 A MX2023000763 A MX 2023000763A
Authority
MX
Mexico
Prior art keywords
antibodies
treatment
neutrophilic dermatoses
present
neutrophilic
Prior art date
Application number
MX2023000763A
Other languages
English (en)
Inventor
Steven John Padula
Janine Lamar
Sudha Visvanathan
Meera RAMANUJAM
Jay Fine
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2023000763A publication Critical patent/MX2023000763A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar, prevenir o mejorar una dermatosis neutrófila. Los métodos de la presente invención incluyen administrar a un paciente que tiene una dermatosis neutrófila una composición farmacéutica que incluye un anticuerpo contra el receptor de interleucina 36 (anti-IL-36R).
MX2023000763A 2020-07-17 2021-07-15 Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas. MX2023000763A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063053129P 2020-07-17 2020-07-17
PCT/US2021/041734 WO2022015920A1 (en) 2020-07-17 2021-07-15 Anti-il-36r antibodies for the treatment of neutrophilic dermatoses

Publications (1)

Publication Number Publication Date
MX2023000763A true MX2023000763A (es) 2023-02-13

Family

ID=77265246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000763A MX2023000763A (es) 2020-07-17 2021-07-15 Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.

Country Status (12)

Country Link
US (1) US20220073628A1 (es)
EP (1) EP4182022A1 (es)
JP (1) JP2023534955A (es)
KR (1) KR20230038774A (es)
CN (1) CN116745315A (es)
AU (1) AU2021309957A1 (es)
BR (1) BR112022026999A2 (es)
CA (1) CA3188382A1 (es)
CL (1) CL2023000121A1 (es)
MX (1) MX2023000763A (es)
TW (1) TW202225190A (es)
WO (1) WO2022015920A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022150642A1 (en) * 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3536710A1 (en) 2011-11-16 2019-09-11 Boehringer Ingelheim International GmbH Anti il-36r antibodies
JP6913026B2 (ja) * 2015-04-15 2021-08-04 アナプティスバイオ インコーポレイティッド インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体
WO2019177888A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
AU2019308205A1 (en) * 2018-07-16 2020-11-19 Regeneron Pharmaceuticals, Inc. Non-human animal models of DITRA disease and uses thereof
BR112021010789A2 (pt) * 2018-12-27 2021-08-31 Boehringer Ingelheim International Gmbh Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
JP7420827B2 (ja) * 2019-03-08 2024-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ－３６ｒ抗体製剤
JP2024517784A (ja) * 2021-05-03 2024-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スペソリマブを産生するための方法

Also Published As

Publication number Publication date
KR20230038774A (ko) 2023-03-21
CA3188382A1 (en) 2022-01-20
AU2021309957A1 (en) 2023-02-02
JP2023534955A (ja) 2023-08-15
EP4182022A1 (en) 2023-05-24
CN116745315A (zh) 2023-09-12
CL2023000121A1 (es) 2023-09-08
WO2022015920A1 (en) 2022-01-20
US20220073628A1 (en) 2022-03-10
BR112022026999A2 (pt) 2023-01-24
TW202225190A (zh) 2022-07-01

Similar Documents

Publication Publication Date Title
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MX2022013163A (es) Anticuerpo contra nectin-4 y aplicacion del mismo.
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
UA94899C2 (ru) Фиксированное дозирование антител к her
BR112022000377A2 (pt) Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r
EA202091747A1 (ru) Составы антитела b7-h4
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2023004399A (es) Tratamiento de combinacion.
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
SG148186A1 (en) Methods and reagents for the treatment of inflammatory disorders
CR20230259A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
MX2021006242A (es) Formulaciones de capsula.
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
WO2023016826A3 (en) Method and means for enhancing therapeutic antibodies
MX2023001055A (es) Inmunógenos derivados de la proteína de la espícula del sars-cov2.
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2023001481A (es) Metodos para tratar pacientes con hipercolesterolemia refractaria.
JP2017165711A (ja) 放射線感受性を調節するためのｈｅｒ３阻害剤